ReviewCell host & microbe2020
The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.
Review in Cell host & microbe, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06250881 (Analysis of Ocular Complications of AIDS Patients in Ophthalmic Consultation), which is not on this map. Cited by 206 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Analysis of Ocular Complications of AIDS Patients in Ophthalmic Consultation
Who cites it
206 citing papers in PubMed.
- Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV.eLife · 2026Trial
- Trial
- Circular RNA functions in HIV-1 infection.RNA biology · 2026Review
- Brain viral reservoir seeding and neurological metabolic dysregulation in early-life immunodeficiency virus infection.Brain pathology (Zurich, Switzerland) · 2026Article
- Article
- HIV immunological nonresponders show low SKAP1 concentration and DNA hypermethylation in the SKAP1 promotor region.AIDS (London, England) · 2026Article
- HCV-specific CD4EBioMedicine · 2026Article
- HIV tri-specific killer engagers directly enhance NK cell function and safely expand NK cells in vivo.Cell reports. Medicine · 2026Article
- Opportunities and challenges in achieving a functional cure for HIV.Infectious diseases & immunity · 2026Review
- Targeting rapidly cycling receptors CD2 and CD7 increases nanoparticle delivery to primary CD4Nature communications · 2026Article
- Modeling quantifies in vivo neutralization, Fc-mediated killing, and resistance in human clinical trials of five anti-HIV broadly neutralizing antibodies.bioRxiv : the preprint server for biology · 2026Article
- HIV-1 establishes immediate latency in T cells expressing the viral Nef protein.FEBS open bio · 2026Article
- Nef and Vpu protect infected cells from ADCP mediated by plasma from people with HIV-1.bioRxiv : the preprint server for biology · 2026Article
- From Epigenetic Regulation to Protein Degradation: Emerging Strategies for Anti-Infective Drug Discovery.International journal of molecular sciences · 2026Review
- Immune checkpoint landscape in CD4⁺ T cells stratifies HIV-infected individuals by clinical progression.Immunologic research · 2026Article
- Recurrent mutations drive rapid HIV escape from two broadly neutralizing antibodies in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Roles of the cGAS-STING signaling pathway in viral latency.Journal of virology · 2026Review
- Histone decrotonylation plays a distinct role in HIV latency.Science advances · 2026Article
- mGem: Opening Env and harnessing NK cell effector functions to eliminate HIV-1-infected cells.mBio · 2026Review
- Atlas of HIV cis-regulatory elements reveals extensive transcriptional variation across clades, isolates, and within individuals.bioRxiv : the preprint server for biology · 2026Article
146 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Antiretroviral therapy (ART) inhibits HIV replication but is not curative. During ART, the integrated HIV genome persists indefinitely within CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.